Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC

PURPOSE: Treatment with PD-(L)1 blockade can produce remarkably durable responses in non-small cell lung cancer (NSCLC) patients. However, a significant fraction of long-term responders ultimately progress and predictors of late progression are unknown. We hypothesized that circulating tumor DNA (ct...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Hellmann, Matthew D., Nabet, Barzin Y, Rizvi, Hira, Chaudhuri, Aadel A., Wells, Danny K., Dunphy, Mark, Chabon, Jacob J., Liu, Chih Long, Hui, Angela B., Arbour, Kathryn C, Luo, Jia, Preeshagul, Isabel R., Moding, Everett J., Almanza, Diego, Bonilla, Rene F., Sauter, Jennifer L., Choi, Hyejin, Tenet, Megan, Abu-Akeel, Mohsen, Plodkowski, Andrew J., Johnston, Rocio Perez, Yoo, Christopher, Ko, Ryan B., Stehr, Henning, Gojenola, Linda, Wakelee, Heather A., Padda, Sukhmani K., Neal, Joel W., Chaft, Jamie E., Kris, Mark G., Rudin, Charles M., Merghoub, Taha, Li, Bob T., Alizadeh, Ash, Diehn, Maximilian
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7299781/
https://ncbi.nlm.nih.gov/pubmed/32046999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3418
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars